Cargando…

Applicability of the DPRA on mixture testing: challenges and opportunities

The in chemico direct peptide reactivity assay (DPRA) is validated to assess protein reactivity of chemical compounds, relating to the molecular initiating event of skin sensitization induction. According to OECD TG 442C, the DPRA is technically applicable to test multi-constituent substances and mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcelis, Quinten, Deconinck, Eric, Rogiers, Vera, Vanhaecke, Tamara, Desmedt, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404183/
https://www.ncbi.nlm.nih.gov/pubmed/37414884
http://dx.doi.org/10.1007/s00204-023-03551-y
_version_ 1785085240341954560
author Marcelis, Quinten
Deconinck, Eric
Rogiers, Vera
Vanhaecke, Tamara
Desmedt, Bart
author_facet Marcelis, Quinten
Deconinck, Eric
Rogiers, Vera
Vanhaecke, Tamara
Desmedt, Bart
author_sort Marcelis, Quinten
collection PubMed
description The in chemico direct peptide reactivity assay (DPRA) is validated to assess protein reactivity of chemical compounds, relating to the molecular initiating event of skin sensitization induction. According to OECD TG 442C, the DPRA is technically applicable to test multi-constituent substances and mixtures of known composition, even though limited experimental data are publicly available. First, we assessed the DPRA’s predictive capability for individual substances, but at concentrations other than the recommended 100 mM, i.e., based on the LLNA EC3 concentration (Experiment A). Next, the applicability of the DPRA to test unknown mixtures was assessed (Experiment B). Here, the complexity of unknown mixtures was reduced to mixtures containing either two known skin sensitizers with varying potencies, or a combination of a skin sensitizer with a non-skin sensitizer, or multiple non-sensitizers. Experiments A and B revealed that one extremely potent sensitizer (oxazolone) was incorrectly classified as a non-sensitizer when tested at its low EC3 concentration of 0.4 mM instead of the suggested molar excess conditions of 100 mM (Experiments A). For binary mixtures tested in experiments B, the DPRA was able to distinguish all skin sensitizers and the strongest skin sensitizer in the mixture was determinant for the overall peptide depletion of a sensitizer. In conclusion, we confirmed that the DPRA test method can be used efficiently for well-known characterized mixtures. However, when deviating from the recommended testing concentration of 100 mM, caution should be taken in case of negative results, limiting the DPRA’s applicability for mixtures of unknown composition. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00204-023-03551-y.
format Online
Article
Text
id pubmed-10404183
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-104041832023-08-07 Applicability of the DPRA on mixture testing: challenges and opportunities Marcelis, Quinten Deconinck, Eric Rogiers, Vera Vanhaecke, Tamara Desmedt, Bart Arch Toxicol Immunotoxicology The in chemico direct peptide reactivity assay (DPRA) is validated to assess protein reactivity of chemical compounds, relating to the molecular initiating event of skin sensitization induction. According to OECD TG 442C, the DPRA is technically applicable to test multi-constituent substances and mixtures of known composition, even though limited experimental data are publicly available. First, we assessed the DPRA’s predictive capability for individual substances, but at concentrations other than the recommended 100 mM, i.e., based on the LLNA EC3 concentration (Experiment A). Next, the applicability of the DPRA to test unknown mixtures was assessed (Experiment B). Here, the complexity of unknown mixtures was reduced to mixtures containing either two known skin sensitizers with varying potencies, or a combination of a skin sensitizer with a non-skin sensitizer, or multiple non-sensitizers. Experiments A and B revealed that one extremely potent sensitizer (oxazolone) was incorrectly classified as a non-sensitizer when tested at its low EC3 concentration of 0.4 mM instead of the suggested molar excess conditions of 100 mM (Experiments A). For binary mixtures tested in experiments B, the DPRA was able to distinguish all skin sensitizers and the strongest skin sensitizer in the mixture was determinant for the overall peptide depletion of a sensitizer. In conclusion, we confirmed that the DPRA test method can be used efficiently for well-known characterized mixtures. However, when deviating from the recommended testing concentration of 100 mM, caution should be taken in case of negative results, limiting the DPRA’s applicability for mixtures of unknown composition. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00204-023-03551-y. Springer Berlin Heidelberg 2023-07-07 2023 /pmc/articles/PMC10404183/ /pubmed/37414884 http://dx.doi.org/10.1007/s00204-023-03551-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Immunotoxicology
Marcelis, Quinten
Deconinck, Eric
Rogiers, Vera
Vanhaecke, Tamara
Desmedt, Bart
Applicability of the DPRA on mixture testing: challenges and opportunities
title Applicability of the DPRA on mixture testing: challenges and opportunities
title_full Applicability of the DPRA on mixture testing: challenges and opportunities
title_fullStr Applicability of the DPRA on mixture testing: challenges and opportunities
title_full_unstemmed Applicability of the DPRA on mixture testing: challenges and opportunities
title_short Applicability of the DPRA on mixture testing: challenges and opportunities
title_sort applicability of the dpra on mixture testing: challenges and opportunities
topic Immunotoxicology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404183/
https://www.ncbi.nlm.nih.gov/pubmed/37414884
http://dx.doi.org/10.1007/s00204-023-03551-y
work_keys_str_mv AT marcelisquinten applicabilityofthedpraonmixturetestingchallengesandopportunities
AT deconinckeric applicabilityofthedpraonmixturetestingchallengesandopportunities
AT rogiersvera applicabilityofthedpraonmixturetestingchallengesandopportunities
AT vanhaecketamara applicabilityofthedpraonmixturetestingchallengesandopportunities
AT desmedtbart applicabilityofthedpraonmixturetestingchallengesandopportunities